Pregabalina i duloksetyna w praktyce psychiatry. Najczęściej pojawiające się pytania i wątpliwości Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2019
Słowa kluczowe:
pregabalina, duloksetyna, SNRI, GABA, lęk uogólniony, depresja, wenlafaksyna, benzodiazepiny
##plugins.themes.bootstrap3.article.main##
Abstrakt
Pregabalina początkowo była rozwijana jako lek przeciwpadaczkowy, później zaś znalazła zastosowanie w innych wskazaniach, zwłaszcza w lęku uogólnionym i bólu neuropatycznym. Duloksetyna zaś początkowo była stosowana w terapii neuropatii cukrzycowej, ale w kolejnych latach zarejestrowano ją w leczeniu epizodów dużej depresji i lęku uogólnionego. Oba leki odznaczają się dużą skutecznością, jednak ich stosowanie ograniczają wskazania refundacyjne. W pracy przedstawiono sytuacje, w których wykorzystanie tych leków może przynieść znaczące korzyści.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sobów, T. (2019). Pregabalina i duloksetyna w praktyce psychiatry. Najczęściej pojawiające się pytania i wątpliwości. Medycyna Faktów , 12(2(43), 132-135. https://doi.org/10.24292/01.MF.0219.7
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Schueler Y.B., Koesters M., Wieseler B. et al.: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr. Scand. 2011; 123: 247-265.
2. Cipriani A., Koesters M., Furukawa T.A., et al.: Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2014; 10: CD006533.
3. Girardi P., Pompili M., Innamorati M. et al.: Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum. Psychopharmacol. 2009; 24(3): 177-190.
4. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006; 188: 346-353.
5. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
6. Dunner D.L., Goldstein D.J., Mallinckrodt C. et al.: Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety 2003; 18: 53-61.
7. Fava M., Mallinckrodt C.H., Detke M.J. et al.: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 2004; 65(4): 521-530.
8. Tokuoka H., Nishihara M., Fujikoshi S. et al.: Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine. Neuropsychiatr. Dis. Treat. 2017; 13: 2457-2467.
9. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13(3): 227-235.
10. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
11. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G. et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
12. Hidalgo R.B., Tupler L.A., Davidson J.R.: An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol. 2007; 21: 864-872.
13. Bandelow B., Sher L., Bunevicius R. et al.: Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 2012; 16: 77-84.
14. Baldwin D.S., Anderson I.M., Nutt D.J. et al.: Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J. Psychopharmacol. 2014; 28(5): 403-439.
15. Katzman M.A., Bleau P., Blier P. et al.: Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive- compulsive disorders. BMC Psychiatry 2014; 14(supl. 1): S1.
2. Cipriani A., Koesters M., Furukawa T.A., et al.: Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2014; 10: CD006533.
3. Girardi P., Pompili M., Innamorati M. et al.: Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. Hum. Psychopharmacol. 2009; 24(3): 177-190.
4. Perahia D.G., Gilaberte I., Wang F. et al.: Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br. J. Psychiatry 2006; 188: 346-353.
5. Perahia D.G., Maina G., Thase M.E. et al.: Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009b; 70: 706-716.
6. Dunner D.L., Goldstein D.J., Mallinckrodt C. et al.: Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety 2003; 18: 53-61.
7. Fava M., Mallinckrodt C.H., Detke M.J. et al.: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 2004; 65(4): 521-530.
8. Tokuoka H., Nishihara M., Fujikoshi S. et al.: Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine. Neuropsychiatr. Dis. Treat. 2017; 13: 2457-2467.
9. Nelson J.C., Wohlreich M.M., Mallinckrodt C.H. et al.: Duloxetine for the treatment of major depressive disorder in older patients. Am. J. Geriatr. Psychiatry 2005; 13(3): 227-235.
10. Raskin J., Wiltse C.G., Siegal A. et al.: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am. J. Psychiatry 2007; 164: 900-909.
11. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G. et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
12. Hidalgo R.B., Tupler L.A., Davidson J.R.: An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol. 2007; 21: 864-872.
13. Bandelow B., Sher L., Bunevicius R. et al.: Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 2012; 16: 77-84.
14. Baldwin D.S., Anderson I.M., Nutt D.J. et al.: Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J. Psychopharmacol. 2014; 28(5): 403-439.
15. Katzman M.A., Bleau P., Blier P. et al.: Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive- compulsive disorders. BMC Psychiatry 2014; 14(supl. 1): S1.